FibroBiologics, Inc. Common Stock
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $7.9M
- Price
- $1.13
- % Change (Daily % change from the live per-ticker quote feed.)
- -4.24%
- Volume
- 210.3K
About
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
Quick stats
Shares outstanding7.0M
Computed float6.2M
Float / shares89.2%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001958777
AI Summary
AI-generated1/39
minorneutralother
Nova Minerals and FibroBiologics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
FibroBiologics CEO Pete O'Heeron will appear on the RedChip Small Stocks, Big Money show airing on Bloomberg TV September 26 and CNBC September 27, discussing the company's fibroblast-based cell therapy platform.
Key topics include the ongoing Phase 1/2 diabetic foot ulcer study with data expected this year, a psoriasis IND under FDA review, and preclinical programs in multiple sclerosis, degenerative disc disease, thymus regeneration and oncology.
This is a paid, sponsored investor-relations promotion — FBLG is a RedChip client — and contains no new clinical or financial results.
Red flags
- Sponsored, paid investor-relations content (RedChip client) — promotional, not independent coverage
- No new clinical data or financial results disclosed